A clinical trial of a combination therapy using anti-PD-1, anti-CD137, and tumor-infiltrating lymphocytes in patients with advanced melanoma is ongoing and the clinical outcomes of combination therapies using peptide plus nivolumab or peptide plus nivolumab and ipilimumab for advanced melanoma have recently been disclosed [62]. This evidence concerns the gene TNFRSF9 and neoplasm.